# D-allose suppresses colitis associated carcinogenesis by reversing ER stress in macrophages and inhibiting cancer cell proliferation

**Authors:** Xiaodong Li, Keizo Hiraishi, Kensuke Kumamoto, Shin-ichi Nakakita, Tetsuo Yamashita, Kazuyo Kamitori, Kiyomi Ohmichi, Ryou Ishikawa, Lin Hai Kurahara

PMC · DOI: 10.3389/fimmu.2026.1737504 · Frontiers in Immunology · 2026-02-20

## TL;DR

D-allose reduces colon cancer risk in inflammatory bowel disease by reducing stress in immune cells and slowing cancer cell growth.

## Contribution

D-allose is shown to reverse ER stress in macrophages and inhibit cancer cell proliferation in colitis-associated carcinogenesis.

## Key findings

- D-allose reduced tumor number, inflammation, and macrophage infiltration in a mouse model of colitis-associated cancer.
- D-allose suppressed ER stress and mitochondrial dysfunction in macrophages and inhibited cancer cell migration and proliferation.
- ER stress markers were found in macrophages from IBD patients, suggesting a link to inflammation-driven cancer.

## Abstract

Inflammatory bowel diseases (IBD), especially ulcerative colitis, are associated with a high risk of carcinogenesis. D-allose, a D-glucose epimer, exhibits antioxidant and antitumor activities. This study aimed to examine the effects of D-allose on colitis-associated carcinogenesis.

A mouse model of colitis-associated carcinogenesis was established followed by treatment with D-allose. In vitro, ER stress and mitochondrial function in RAW 264.7 macrophages and the migration and proliferation of Caco-2 cells were analyzed to elucidate the underlying mechanisms. Colonic tissues obtained from IBD patients with were subjected to analyze ER stress in macrophages.

D-allose administration significantly reduced the tumor number, hemorrhage, inflammation score, and macrophage infiltration in the AOM/DSS model. D-allose suppressed ER stress signal and mitochondrial dysfunction in LPS treated RAW 264.7 macrophages. D-allose suppressed ER stress marker Bip and CHOP expression in thapsigargin treated RAW 264.7. In IBD patient’s colon, ER stress marker Bip and CHOP positive macrophage infiltration was detected in both inflammatory and tumor areas. The level of fluorescence labeled M6~G1M9 oligosaccharides increased in the LPS-treated RAW 264.7 macrophages, while thapsigargin or D-allose had no effect. In Caco-2 cells, D-allose suppressed phosphorylated AMPK expression, reduced migratory activity. D-allose inhibited glycolysis, and decreased cell proliferation through TXNIP upregulation.

D-allose suppressed inflammation and tumor development in a colitis-associated carcinogenesis model. D-allose restoring macrophage ER stress and mitochondrial dysfunction, and inhibiting colon cancer cell migration and proliferation. Therefore, D-allose may represent as a promising therapeutic and preventive agent for IBD and inflammation-associated carcinogenesis.

## Linked entities

- **Proteins:** GDF10 (growth differentiation factor 10), DDIT3 (DNA damage inducible transcript 3), PRKAA1 (protein kinase AMP-activated catalytic subunit alpha 1), TXNIP (thioredoxin interacting protein)
- **Chemicals:** D-allose (PubChem CID 102288), D-glucose (PubChem CID 5793), thapsigargin (PubChem CID 446378)
- **Diseases:** ulcerative colitis (MONDO:0005101)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** TXNIP (thioredoxin interacting protein) [NCBI Gene 10628] {aka ARRDC6, EST01027, HHCPA78, THIF, VDUP1}, Mrc1 (mannose receptor, C type 1) [NCBI Gene 17533] {aka CD206, MR}, CD68 (CD68 molecule) [NCBI Gene 968] {aka GP110, LAMP4, SCARD1}, Cdkn1b (cyclin dependent kinase inhibitor 1B) [NCBI Gene 12576] {aka Kip1, p27, p27Kip1}, CALCR (calcitonin receptor) [NCBI Gene 799] {aka CRT, CT-R, CTR, CTR1}, Il6 (interleukin 6) [NCBI Gene 16193] {aka Il-6}, Calr (calreticulin) [NCBI Gene 12317] {aka CRT, Calregulin}, DDIT3 (DNA damage inducible transcript 3) [NCBI Gene 1649] {aka AltDDIT3, C/EBPzeta, CEBPZ, CHOP, CHOP-10, CHOP10}, Il1b (interleukin 1 beta) [NCBI Gene 16176] {aka IL-1beta, Il-1b}, Tlr4 (toll-like receptor 4) [NCBI Gene 21898] {aka Lps, Ly87, Ran/M1, Rasl2-8}, Cd68 (CD68 antigen) [NCBI Gene 12514] {aka Lamp4, Scard1, gp110}, Canx (calnexin) [NCBI Gene 12330] {aka 1110069N15Rik, Cnx, D11Ertd153e}, SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513] {aka CSE, DYT17, DYT18, DYT9, EIG12, GLUT}, PRKAA2 (protein kinase AMP-activated catalytic subunit alpha 2) [NCBI Gene 5563] {aka AMPK, AMPK2, AMPKa2, PRKAA}, Hspa5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 14828] {aka Bip, D2Wsu141e, D2Wsu17e, Grp78, Hsce70, SEZ-7}, MYL2 (myosin light chain 2) [NCBI Gene 4633] {aka CMH10, MFM12, MLC-2, MLC-2s/v, MLC-2v, MLC2}, HSPA5 (heat shock protein family A (Hsp70) member 5) [NCBI Gene 3309] {aka BIP, GRP78, HEL-S-89n}, GDF10 (growth differentiation factor 10) [NCBI Gene 2662] {aka BIP, BMP-3b, BMP3B}, Tnf (tumor necrosis factor) [NCBI Gene 21926] {aka DIF, TNF-a, TNF-alpha, TNFSF2, TNFalpha, Tnfa}, Txnip (thioredoxin interacting protein) [NCBI Gene 56338] {aka 1200008J08Rik, Hyplip1, THIF, Tbp-2, VDUP1}, Ddit3 (DNA-damage inducible transcript 3) [NCBI Gene 13198] {aka AltDDIT3, CHOP-10, CHOP10, chop, gadd153}, Nos2 (nitric oxide synthase 2, inducible) [NCBI Gene 18126] {aka MAC-NOS, NOS-II, Nos-2, Nos2a, i-NOS, iNOS}, DNAH8 (dynein axonemal heavy chain 8) [NCBI Gene 1769] {aka ATPase, SPGF46, hdhc9}, MLC1 (modulator of VRAC current 1) [NCBI Gene 23209] {aka LVM, MLC, VL}
- **Diseases:** bleeding (MESH:D006470), Anal tumor prolapse (MESH:D001005), carcinogenesis (MESH:D063646), metabolic dysfunction (MESH:D008659), colon carcinoma (MESH:D003110), inflammation (MESH:D007249), Fibrosis (MESH:D005355), mitochondrial dysfunction (MESH:D028361), ovarian, prostate, head and neck, leukemia, cervical, and skin cancers (MESH:D013577), adenocarcinomas (MESH:D000230), cancer (MESH:D009369), rectal bleeding (MESH:D012002), head and neck cancer (MESH:D006258), enteritis (MESH:D004751), IBD (MESH:D015212), polyps (MESH:D011127), CAC (MESH:D000083023), hepatocellular carcinoma (MESH:D006528), dislocation (MESH:D004204), UC (MESH:D003093), colon (MESH:D003108), chronic inflammatory diseases (MESH:D002908), metastasis (MESH:D009362), carcinogenic (MESH:D011230), colon cancer (MESH:D015179), CD (MESH:D003424), colitis (MESH:D003092), toxicity (MESH:D064420)
- **Chemicals:** phenol (MESH:D019800), water (MESH:D014867), 2-aminopyridine (MESH:C032439), HCl (MESH:D006851), acetic acid (MESH:D019342), SDS (MESH:D012967), Alexa Fluor 555 (MESH:C000608607), ethanol (MESH:D000431), paraffin (MESH:D010232), pyruvate (MESH:D019289), NaCl (MESH:D012965), thapsigargin (MESH:D019284), sodium deoxycholate (MESH:D003840), methanol (MESH:D000432), ammonium formate (MESH:C030544), sugars (MESH:D000073893), AOM (MESH:D001397), phalloidin (MESH:D010590), Nonidet P40 (MESH:C010615), glycans (MESH:D011134), Triton X-100 (MESH:D017830), monosaccharide (MESH:D009005), acetonitrile (MESH:C032159), 2-deoxy glucose (MESH:D003847), polyacrylamide (MESH:C016679), streptomycin (MESH:D013307), ATP (MESH:D000255), dextran sulfate sodium (MESH:D016264), glutamine (MESH:D005973), citric acid (MESH:D019343), rotenone (MESH:D012402), CO2 (MESH:D002245), chloroform (MESH:D002725), antimycin A (MESH:D000968), LPS (MESH:D008070), TO-PRO-3 (MESH:C098830), eosin (MESH:D004801), PVDF (MESH:C024865), 4',6-diamidino-2-phenylindole (MESH:C007293), D-glucose (MESH:D005947), formalin (MESH:D005557), ROS (MESH:D017382), Oligomycin (MESH:D009840), D (MESH:D003903), A5486 (-), H&amp;E (MESH:D006371), Crystal violet (MESH:D005840), oligosaccharide (MESH:D009844), allose (MESH:C002055), JC-1 (MESH:C068624), hematoxylin (MESH:D006416), penicillin (MESH:D010406), Lipofectamine (MESH:C086724), fluorescein (MESH:D019793), amino acids (MESH:D000596), Can (MESH:C004653), Alexa Fluor 488 (MESH:C000711379)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** RCB-0988 — Homo sapiens (Human), Transformed cell line (CVCL_K741), RAW 264.7 — Mus musculus (Mouse), Mouse leukemia, Cancer cell line (CVCL_0493), Caco-2 — Homo sapiens (Human), Colon adenocarcinoma, Cancer cell line (CVCL_0025)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963985/full.md

## Figures

8 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963985/full.md

## References

35 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963985/full.md

---
Source: https://tomesphere.com/paper/PMC12963985